Combined ARHGEF6 and Tumor Mutational Burden May Serve As a Potential Biomarker for Immunotherapy of Lung Adenocarcinoma

Overview

Journal Heliyon

Specialty Social Sciences

Date 2023 Aug 21

PMID 37600416

Authors

Li Tong

Sichu Wang

Juanjuan Yang

Qing Zhang

Xue Gu

Taoming Mo

Yang Luo

Chenqian Zhang

Jianguo Zhang

Yifei Liu

Affiliations

Soon will be listed here.

Abstract

ARHGEF6, a member of the Dbl-related guanylate exchanger (GEF) family, is highly expressed in gastric cancer and glioma. However, scientists still do not know whether it plays a pivotal role in the pathogenesis of lung adenocarcinoma（LUAD）. The prognostic significance of ARHGEF6 expression was assessed by TCGA data. This paper focuses on the level of immune infiltration associated with ARHGEF6 and explored the relationship of this gene with the tumor mutational burden (TMB), immune checkpoints, and drug sensitivity. The results showed that the high expression of ARHGEF6 was associated with a good prognosis in LUAD patients, and positively correlated with a variety of immune cells and drugs. Meanwhile, ARHGEF6 was found to be negatively correlated with TMB. In conclusion, the results of this study suggest that ARHGEF6 is a protective gene in LUAD patients. A combination of ARHGEF6 and TMB could be used as a potential biomarker in the screening of immunotherapy regimens, which are provided to patients with LUAD.

References

Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky J, Desrichard A . Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014; 371(23):2189-2199. PMC: 4315319. DOI: 10.1056/NEJMoa1406498. View

Joseph J, Radulovich N, Wang T, Raghavan V, Zhu C, Tsao M . Rho guanine nucleotide exchange factor ARHGEF10 is a putative tumor suppressor in pancreatic ductal adenocarcinoma. Oncogene. 2019; 39(2):308-321. DOI: 10.1038/s41388-019-0985-1. View

Baird D, Feng Q, Cerione R . The Cool-2/alpha-Pix protein mediates a Cdc42-Rac signaling cascade. Curr Biol. 2005; 15(1):1-10. DOI: 10.1016/j.cub.2004.12.040. View

Ru B, Wong C, Tong Y, Zhong J, Zhong S, Wu W . TISIDB: an integrated repository portal for tumor-immune system interactions. Bioinformatics. 2019; 35(20):4200-4202. DOI: 10.1093/bioinformatics/btz210. View

Stenzinger A, Allen J, Maas J, Stewart M, Merino D, Wempe M . Tumor mutational burden standardization initiatives: Recommendations for consistent tumor mutational burden assessment in clinical samples to guide immunotherapy treatment decisions. Genes Chromosomes Cancer. 2019; 58(8):578-588. PMC: 6618007. DOI: 10.1002/gcc.22733. View

Hellmann M, Ciuleanu T, Pluzanski A, Lee J, Otterson G, Audigier-Valette C . Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. N Engl J Med. 2018; 378(22):2093-2104. PMC: 7193684. DOI: 10.1056/NEJMoa1801946. View

Yang W, Soares J, Greninger P, Edelman E, Lightfoot H, Forbes S . Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 2012; 41(Database issue):D955-61. PMC: 3531057. DOI: 10.1093/nar/gks1111. View

Rizvi H, Sanchez-Vega F, La K, Chatila W, Jonsson P, Halpenny D . Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. J Clin Oncol. 2018; 36(7):633-641. PMC: 6075848. DOI: 10.1200/JCO.2017.75.3384. View

Li J, Yang G, Luo X, Mo L, Qiu S, Yang L . Interaction between Ras and Bcl2L12 in B cells suppresses IL-10 expression. Clin Immunol. 2021; 229:108775. DOI: 10.1016/j.clim.2021.108775. View

10.

Huang M, Jiang X, Wang B, Sun Y, Lu J . Combination therapy with PD-1/PD-L1 blockade in non-small cell lung cancer: strategies and mechanisms. Pharmacol Ther. 2020; 219:107694. DOI: 10.1016/j.pharmthera.2020.107694. View

11.

Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q . TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020; 48(W1):W509-W514. PMC: 7319575. DOI: 10.1093/nar/gkaa407. View

12.

Jurisic V, Vukovic V, Obradovic J, Gulyaeva L, Kushlinskii N, Djordjevic N . Polymorphism and Survival of NSCLC Patients Treated with TKIs: A Systematic Review and Meta-Analysis. J Oncol. 2020; 2020:1973241. PMC: 7104312. DOI: 10.1155/2020/1973241. View

13.

Huang D, Wang Y, Xu L, Chen L, Cheng M, Shi W . GLI2 promotes cell proliferation and migration through transcriptional activation of ARHGEF16 in human glioma cells. J Exp Clin Cancer Res. 2018; 37(1):247. PMC: 6180656. DOI: 10.1186/s13046-018-0917-x. View

14.

Lei X, Deng L, Liu D, Liao S, Dai H, Li J . ARHGEF7 promotes metastasis of colorectal adenocarcinoma by regulating the motility of cancer cells. Int J Oncol. 2018; 53(5):1980-1996. PMC: 6192735. DOI: 10.3892/ijo.2018.4535. View

15.

Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M . Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 2018; 103:356-387. DOI: 10.1016/j.ejca.2018.07.005. View

16.

Yokota T, Kouno J, Adachi K, Takahashi H, Teramoto A, Matsumoto K . Identification of histological markers for malignant glioma by genome-wide expression analysis: dynein, alpha-PIX and sorcin. Acta Neuropathol. 2005; 111(1):29-38. DOI: 10.1007/s00401-005-1085-6. View

17.

Kutsche K, Yntema H, Brandt A, Jantke I, Nothwang H, Orth U . Mutations in ARHGEF6, encoding a guanine nucleotide exchange factor for Rho GTPases, in patients with X-linked mental retardation. Nat Genet. 2000; 26(2):247-50. DOI: 10.1038/80002. View

18.

Yu Y, Zeng D, Ou Q, Liu S, Li A, Chen Y . Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis. JAMA Netw Open. 2019; 2(7):e196879. PMC: 6625073. DOI: 10.1001/jamanetworkopen.2019.6879. View

19.

Zhang L, Chen Y, Wang H, Xu Z, Wang Y, Li S . Massive PD-L1 and CD8 double positive TILs characterize an immunosuppressive microenvironment with high mutational burden in lung cancer. J Immunother Cancer. 2021; 9(6). PMC: 8212410. DOI: 10.1136/jitc-2021-002356. View

20.

Sun D, Wang J, Han Y, Dong X, Ge J, Zheng R . TISCH: a comprehensive web resource enabling interactive single-cell transcriptome visualization of tumor microenvironment. Nucleic Acids Res. 2020; 49(D1):D1420-D1430. PMC: 7778907. DOI: 10.1093/nar/gkaa1020. View